INTRODUCTION
is a small dimeric molecule with bactericidal properties against a broad spectrum of bacteria ranging from anaerobic to aerobic species. 1, 2, 3 Tauroldine's mechanism of action as an antibiotic agent is associated with a chemical reaction between the active TRD metabolites, taurultam [TRT] and taurinamide [TRM] with the structures of bacterial wall. 3, 6 In addition, TRD exhibits the ability to neutralize bacterial endotoxins, exotoxins and lipopolysaccharides. 7, 8, 9 The most widespread clinical application of TRD at present is as a catheter lock solution to reduce the incidence of vascular access-associated blood stream infections. Other clinical applications have included peritoneal lavage for prophylaxis against post-operational bacterial infections in patients with established peritonitis following elective colorectal surgeries, and as an antiendotoxic agent in patients with systemic inflammatory response syndrome. 2, 3, 10 TRD has also been investigated extensively as an experimental anti-neoplastic agent in in vitro and in vivo studies. 11, 12, 13, 14 It appears to have a direct effect on various tumor cell lines with a consecutive inhibition in cell growth. 12, 15 Preclinical investigations have suggested activity against colon, ovarian, and prostate cancer, as well as melanoma, and mesothelioma. Of significance, intra-peritoneal and systemic application of TRD resulted in a reduction of intra-and extra-peritoneal metastases in rodent models, suggesting utility as a chemopreventive agent against metastases. 11, 16 Indeed,
prophylactic, intra-operative peritoneal lavage with TRD for prevention of metastatic diseases has been successfully applied, while intravenous administration of the agent as 5 the primary treatment of poorly managed malignancies has been currently investigated in clinical trials.
17, 18
Despite administration to over 13,000 patients, the pharmacokinetics of TRD metabolites has not been comprehensively characterized in humans. TRD in aqueous solution undergoes rapid conversion to TRT, with smaller amounts of hydroxymethyltaurultam.
TRT is subsequently converted to TRM [ Figure 1 ]. 19, 20 Because of these metabolic characteristics, the TRD metabolites are more important pharmacokinetic markers than the parent compound in studying its pharmacodynamic properties including antibacterial and anti-neoplastic repertoire. In this study, the pharmacokinetics of TRD metabolites was investigated in healthy volunteers following intravenous administration of TRD solution.
METHODS

Subjects
Healthy male or female subjects between the ages of 18 and 45 years, between 45 and 100 kg and within 20% of ideal body weight range for body frame, were eligible to participate in the present study. The use of prescription medications and tobacco were exclusion criteria. The study was approved by the institutional review board of Thomas Jefferson University. All subjects gave written informed consent to participate prior to undergoing any study-related procedures.
6
Study Design
This was an open labeled, three-arm, single dose, parallel study that compared the pharmacokinetics and safety of [1] performed at baseline and at specified intervals post dose. Twenty-four hours after each treatment, subjects were discharged from the unit.
Collection and determination of analyte concentrations
Blood was drawn for TRT and TRM pharmacokinetics predose, and at 5, 15, 30, 45 min, to 42], participated in the study. Ten subjects were black, 6 white, one Hispanic and one subject was self-described as mixed race. Detailed demographic data is summarized in Table 1 . All subjects completed the study.
Pharmacokinetics
The present study compared the pharmacokinetics of TRD metabolites over 3 different should be considered estimates. Maximum concentrations were reached sooner for TRT in the order of 0.5 hr-infusion < 1 hr-infusion < 2 hr-infusion (p = 0.0017). The T max for TRM occurred essentially at the end of infusion while that of TRT appeared generally to be achieved before completing the infusion (p < 0.05).
Safety
Safety data on all subjects in the trial is reported. There were no serious adverse effects associated with the administration of taurolidine infusions. No hypotension was noted during drug infusion. All subjects noted burning at the infusion site. Five were graded as mild, twelve as moderate, and one subject in the one hour infusion rate group had severe buring that required a decrease in the rate of infusion. Seven subjects also described a numbness or soreness in the infusion arm or shoulder. Four episodes were ranked as mild and three as moderate. Infusion-related symptoms began within one minute of onset and generally ceased at the end of infusion. Four subjects had mild erythematous streaking at the site of the IV, which also resolved quickly after the end of infusion. Five subjects had facial flushing, of which four were mild and one was moderate. Four of the flushing episodes took place in the 0.5 hr-infusion group and one in the 1 hr group. Other adverse events included single occurrences of headache, epistaxis, and nausea. There were no clinically significant abnormalities in vital signs, electrocardiograms, and clinical laboratory tests except one subject with a single elevated prothrombin time value felt to be possibly related to study drug. Previous analytical studies on animal specimens revealed that TRD exists in equilibrium with TRT, which further reversibly converts to TRM and other degradation products [ Figure 1 ]. 19, 20 In a clinical investigation, Erb et al 19 reported a biphasic elimination of TRT in a model-based analysis after IV administration of 1 gram over one hour in six subjects using a different analytic method. Beta t 1/2 was reported as 2.2 h and V d was 162
± 93 L, which is comparable to the findings reported here [ Table 2 ]. In the present study, intravenous infusion of 5.0 g of taurolidine resulted in a smaller AUC for TRT than for TRM and, conversely, a larger Cl for the former than for the latter [ Table 2 and 3 ]. These findings demonstrate that TRT is an unstable and short-lived metabolite. Prior investigations revealed that the antibiotic action of TRD appeared to be related to action 11 of active metabolites methylol TRT and methylol TRM [ Figure 1 ] on bacterial cell walls, 2, 21 while the antitumor activities were likely due to its proapoptotic and antiangiogenic effects on tumor cells.
17, 18
The present study did not include pharmacodynamic measures to define mechanisms of action of each metabolite.
TRD not only acts as an antibacterial agent to suppress infection but also prevents the growth and spread of tumor cells. In oncology patients, intravenous infusions were reported of up to 20 g/day (1,000 ml of 2% TRD), which were ~4 times more than that examined in the present study, and few clinically relevant drug adverse effects were observed. 15, 17, 22 Anti-tumor activity has been noted preclinically at micromolar concentrations in many tumor cell lines. 18 These concentrations were demonstrated for both metabolites in the present study. The PK parameters generated in this study will assist in the rational dose and infusion interval selection in future human clinical trials.
Finally, safety data reported here in healthy adults indicate that local reactions including burning at the infusion site, numbness or soreness of the infusion arm and erythematous streaking at the IV site were the most common adverse effects associated with intravenous TRD administration. Systemic clinically relevant drug toxicities were minimal in this study, in accordance with the other prior clinical investigations related to the low toxicity of this agent. All data are presented as mean ± S.D. 
